研究人员针对 ARID1A 缺陷型卵巢透明细胞癌（OCCC）治疗难题，研究靶向 USP8，发现其可诱导合成致死，有望用于精准治疗。

The Institute of Cancer Research, London, is seeking a partner to continue the development of ARID1A and other BAF-complex genes as cancer biomarkers for predicting sensitivity to ATRi. More about ...

This study has revealed how the ZIC2 gene, in collaboration with the ARID1A-BAF complex, plays a crucial role in a process known as epithelial-to-mesenchymal transition (EMT). This process enables ...

NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation granted by the U.S.

Nuvectis Pharma has released preliminary findings from the ongoing Phase Ib clinical trial of NXP800, aimed at treating patients with platinum-resistant ARID1a-mutated ovarian cancer. The trial ...